Efficacy and safety of linvoseltamab 200 mg in patients with relapsed/refractory multiple myeloma (RRMM): analysis of the LINKER-MM1 study

被引：0

作者：

Dhodapkar, Madhav ^{[1
]}

Bumma, Naresh ^{[2
]}

Richter, Joshua ^{[3
]}

Lee, Hans ^{[4
]}

Hoffman, James ^{[5
]}

Suvannasankha, Attaya ^{[6
,7
]}

Lentzsch, Suzanne ^{[8
]}

Shah, Mansi ^{[9
]}

Zonder, Jeffrey ^{[10
]}

Baz, Rachid ^{[11
]}

Wu, Ka Lung ^{[12
]}

Pianko, Matthew ^{[13
]}

Silbermann, Rebecca ^{[14
]}

Min, Chang-Ki ^{[15
]}

Vekemans, Marie-Christiane Madeleine ^{[16
]}

Munder, Markus ^{[17
]}

Byun, Ja Min ^{[18
]}

Martinez Lopez, Joaquin ^{[19
]}

DeVeaux, Michelle ^{[20
]}

Lorenc, Karen Rodriguez ^{[20
]}

Kroog, Glenn ^{[20
]}

Houvras, Yariv ^{[20
]}

Jagannath, Sundar ^{[1
,21
]}

机构：

[1] Emory Univ, Winship Canc Inst, Atlanta, GA USA

[2] Ohio State Univ, Ctr Comprehens Canc, Columbus, OH USA

[3] Icahn Sch Med Mt Sinai, Tisch Canc Inst, New York, NY USA

[4] Univ Texas MD Anderson Canc Ctr, Dept Lymphoma Myeloma, Houston, TX USA

[5] Univ Miami Hlth Syst, Miami, FL USA

[6] Univ Indianapolis, Simon Canc Ctr, Indianapolis, IN USA

[7] Roudebush VAMC, Indianapolis, IN USA

[8] Rutgers Canc Inst New Jersey, New Brunswick, NJ USA

[9] Columbia Univ, Med Ctr, New York, NY USA

[10] Karmanos Canc Inst, Detroit, MI USA

[11] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA

[12] ZNA Stuivenberg, Dept Hematol, Antwerp, Belgium

[13] Univ Michigan, Rogel Canc Ctr, Sch Med, Ann Arbor, MI USA

[14] Oregon Hlth & Sci Univ, Knight Canc Inst, Portland, OR USA

[15] Seoul St Marys Hosp, Seoul, South Korea

[16] Univ Catholique Louvain UCLouvain, Dept Internal Med, Brussels, Belgium

[17] Johannes Gutenberg Univ Mainz, Univ Med Ctr, Dept Med 3, Mainz, Germany

[18] Seoul Natl Univ, Seoul Natl Univ Hosp, Dept Internal Med, Coll Med, Seoul, South Korea

[19] Univ Complutense, Hosp Univ 12 octubre, CNIO, Madrid, Spain

[20] Regeneron Pharmaceut Inc, Tarrytown, NY USA

[21] Mt Sinai Med Ctr, New York, NY USA

来源：

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2023年 / 23卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P-247

引用

页码：S172 / S172

页数：1

共 50 条

[1] Pharmacokinetics (PK) and Immunogenicity of Linvoseltamab in Patients (pts) with Relapsed/ Refractory Multiple Myeloma (RRMM) in LINKER-MM1
Hazra, Anasuya
Lai, Ching-Ha
Chokshi, Dhruti
Houvras, Yariv
Kroog, Glenn S.
Lorenc, Karen Rodriguez
DiCioccio, A. Thomas
Davis, John
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S57 - S57
[2] Patterns of Response to 200 Mg Linvoseltamab in Patients with Relapsed/Refractory Multiple Myeloma: Longer Follow-Up of the Linker-MM1 Study
Jagannath, Sundar
Richter, Joshua
Dhodapkar, Madhav V.
Hoffman, James E.
Lee, Hans C.
Suvannasankha, Attaya
Shah, Mansi R.
Lentzsch, Suzanne
Zonder, Jeffrey A.
Baz, Rachid
Maly, Joseph J.
Namburi, Swathi
Wu, Ka Lung
Pianko, Matthew
Ye, Jing Christine
Silbermann, Rebecca
Min, Chang-Ki
Vekemans, Marie-Christiane
Munder, Markus
Byun, Ja Min
BLOOD, 2023, 142
[3] LINKER-MM1 study: Linvoseltamab (REGN5458) in patients with relapsed/refractory multiple myeloma.
Lee, Hans C.
Bumma, Naresh
Richter, Joshua Ryan
Dhodapkar, Madhav V.
Hoffman, James E.
Suvannasankha, Attaya
Zonder, Jeffrey A.
Shah, Mansi R.
Lentzsch, Suzanne
Maly, Joseph J.
Ye, Jing Christine
Wu, Ka Lung
DeVeaux, Michelle
Chokshi, Dhruti
Boyapati, Anita
Hazra, Anasuya
Rodriguez-Lorenc, Karen
Kroog, Glenn Scott
Houvras, Yariv J.
Jagannath, Sundar
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[4] Efficacy of Linvoseltamab in Prespecified High Risk Subgroups of Patients with Relapsed/Refractory Multiple Myeloma: Results from LINKER-MM1
Suvannasankha, Attaya
Lee, Hans
Bumma, Naresh
Dhodapkar, Madhav V.
Richter, Joshua
Hoffman, James E.
Shah, Mansi
Lentzsch, Suzanne
Zonder, Jeffrey
Baz, Rachid
Maly, Joseph J.
Namburi, Swathi
Wu, Ka Lung
Pianko, Matthew
Silbermann, Rebecca
Min, Chang-Ki
Vekemans, Marie-Christiane
Munder, Markus
Martinez Lopez, Joaquin
DeVeaux, Michelle
Chokshi, Dhruti
Boyapati, Anita
Kroog, Glenn S.
Houvras, Yariv
Jagannath, Sundar
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S90 - S91
[5] Assessment of health-related quality of life (HRQoL) in triple-class-exposed patients with relapsed or refractory multiple myeloma (RRMM) treated with linvoseltamab in the LINKER-MM1 trial
Hoffman, James E.
Bumma, Naresh
Richter, Joshua Ryan
Dhodapkar, Madhav V.
Lee, Hans C.
Suvannasankha, Attaya
Zonder, Jeffrey A.
Maly, Joseph J.
Shah, Mansi R.
Baz, Rachid C.
DeVeaux, Michelle
Ivanescu, Cristina
Rodriguez-Lorenc, Karen
Kroog, Glenn Scott
Houvras, Yariv J.
Inocencio, Timothy J.
Chi, Lei
Harnett, James
Ma, Qiufei
Jagannath, Sundar
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[6] Health-Related Quality of Life (HRQoL) Among Patients with Triple-Class Exposed Relapsed/Refractory Multiple Myeloma (RRMM) Treated with Linvoseltamab in Linker-MM1: Interim Assessment up to 36 Weeks of Treatment
Hoffman, James E.
Bumma, Naresh
Richter, Joshua
Dhodapkar, Madhav V.
Lee, Hans C.
Suvannasankha, Attaya
Houde, Christiane A.
Maly, Joseph J.
Shah, Mansi R.
Baz, Rachid
Namburi, Swathi
Wu, Ka Lung
Pianko, Matthew
Ye, Jing Christine
Lentzsch, Suzanne
Silbermann, Rebecca
Min, Chang-Ki
Vekemans, Marie-Christiane
Munder, Markus
Byun, Ja Min
Martinez Lopez, Joaquin
DeVeaux, Michelle
Ivanescu, Cristina
Lorenc, Karen Rodriguez
Kroog, Glenn S.
Houvras, Yariv
Inocencio, Timothy J.
Chi, Lei
Harnett, James
Ma, Qiufei
Jagannath, Sundar
BLOOD, 2023, 142
[7] Efficacy and Safety of Ruxolitinib and Steroids for Treating Patients with Relapsed or Refractory Multiple Myeloma (RRMM)
Berenson, James R.
Silagan, Noemi
To, Jennifer
Spektor, Tanya M.
Martinez, Daisy
Sanchez, Armando J.
Forouzan, Eli
Swift, Regina
Eades, Benjamin
Schwartz, Gary
Eshaghian, Shahrooz
Boccia, Ralph V.
Yang, Honghao Hank
Lim, Stephen
Vescio, Robert
BLOOD, 2020, 136
[8] LINKER-MM3, a phase 3, open-label, randomized study of linvoseltamab versus elotuzumab, pomalidomide, and dexamethasone (EPd) in relapsed/refractory multiple myeloma (RRMM)
Weisel, Katja
Hungria, Vania
Quach, Hang
Yoon, Sung-Soo
Rodriguez-Otero, Paula
Sinha, Arijit
Boyapati, Anita
Lyon, Charlotte
Moore, Vygngley
Inocencio, Tim
Harnett, James
Chi, Lei
Lorenc, Karen Rodriguez
Kroog, Glenn
Voorhees, Peter
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S63 - S64
[9] Efficacy and Safety of Elranatamab in Black Patients with Relapsed/Refractory Multiple Myeloma (RRMM): A Subgroup Analysis of the Magnetismm Studies
Varshavsky-Yanovsky, Asya
Jethava, Yogesh
Stevens, Don A.
Nooka, Ajay K.
Stiff, Patrick J.
Perez-Cruz, Isabel
Leip, Eric
Lesokhin, Alexander
BLOOD, 2023, 142
[10] Evaluation of the efficacy and safety of two different linvoseltamab Phase 2 dose regimens: results from LINKER-MM1
Richter, Joshua
Bumma, Naresh
Dhodapkar, Madhav
Hoffman, James
Lee, Hans
Suvannasankha, Attaya
DeVeaux, Michelle
Chokshi, Dhruti
Boyapati, Anita
Hazra, Anasuya
Lorenc, Karen Rodriguez
Kroog, Glenn
Houvras, Yariv
Jagannath, Sundar
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S58 - S59

← 1 2 3 4 5 →